{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T11:40:34Z","timestamp":1717846834294},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T00:00:00Z","timestamp":1427241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Egyptian National Cancer Institute"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.jnci.2015.03.004","type":"journal-article","created":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T12:50:37Z","timestamp":1428929437000},"page":"69-75","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience"],"prefix":"10.1186","volume":"27","author":[{"given":"Wael Abdelgawad","family":"Edesa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raafat Ragaey","family":"Abdel-malek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.jnci.2015.03.004_b0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"10.1016\/j.jnci.2015.03.004_b0010","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project; HAEMACARE Working Group","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jnci.2015.03.004_b0015","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by subtype: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jnci.2015.03.004_b0020","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","article-title":"Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009","volume":"54","author":"Chen","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jnci.2015.03.004_b0025","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"issue":"9584","key":"10.1016\/j.jnci.2015.03.004_b0030","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"On behalf of the European LeukemiaNet. Chronic myeloid leukemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jnci.2015.03.004_b0035","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jnci.2015.03.004_b0040","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jnci.2015.03.004_b0045","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jnci.2015.03.004_b0050","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jnci.2015.03.004_b0055","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jnci.2015.03.004_b0060","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jnci.2015.03.004_b0065","unstructured":"Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 <http:\/\/ctep.cancer.gov>, Publish Date: August 9, 2006."},{"key":"10.1016\/j.jnci.2015.03.004_b0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jnci.2015.03.004_b0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models in life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc"},{"key":"10.1016\/j.jnci.2015.03.004_b0080","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.jnci.2015.03.004_b0085","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.jnci.2015.03.004_b0090","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on Imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jnci.2015.03.004_b0095","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.jnci.2015.03.004_b0100","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European Leukemia Net Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jnci.2015.03.004_b0105","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.jnci.2015.03.004_b0110","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jnci.2015.03.004_b0115","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome positive, chronic myeloid leukaemia: 24-month minimum follow up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jnci.2015.03.004_b0120","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.jnci.2015.03.004_b0125","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jnci.2015.03.004_b0130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2013.9048","article-title":"Predictive value of pretreatment BCR-ABLIS transcript level on response to Imatinib therapy in egyptian patients with chronic phase chronic myeloid leukemia (CPCML)","volume":"9","author":"El-Metnawy","year":"2013","journal-title":"Int J Biomed Sci"},{"key":"10.1016\/j.jnci.2015.03.004_b0135","doi-asserted-by":"crossref","unstructured":"Apperley JF, Szydlo RM, Gerrard G, McCue JR, Wardle J, Clark RE, et al. Dose interruption\/reduction of tyrosine kinase inhibitors in the first 3months of treatment of CML is associated with inferior early molecular responses and predicts for an increased likelihood of discontinuation of the first line agent. Program and abstracts of the 55th American Society of Hematology Annual Meeting and Exposition; December 7\u201310, 2013; New Orleans, Louisiana. Abstract.","DOI":"10.1182\/blood.V122.21.93.93"},{"issue":"5","key":"10.1016\/j.jnci.2015.03.004_b0140","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jnci.2015.03.004_b0145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jnci.2015.03.004_b0150","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"Muller","year":"2009","journal-title":"Leukemia"},{"issue":"28","key":"10.1016\/j.jnci.2015.03.004_b0155","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1200\/JCO.2008.20.3869","article-title":"High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses","volume":"27","author":"Cortes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jnci.2015.03.004_b0160","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","article-title":"Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group","volume":"95","author":"Cervantes","year":"2010","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.jnci.2015.03.004_b0165","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"France Intergroupe des Leu\u0107emies M\u00fdelo\u00a8\u0131des Chroniques (Fi-LMC). Imatinib plus peg interferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med."},{"issue":"21","key":"10.1016\/j.jnci.2015.03.004_b0170","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","article-title":"Gruppo Italiano Malattie Ematologiche dell\u2019Adulto CML Working Party. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party","volume":"117","author":"Gugliotta","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jnci.2015.03.004_b0175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0609.2011.01637.x","article-title":"Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000\u2014a report from the population-based CAMELIA Registry","volume":"87","author":"Faber","year":"2011","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.jnci.2015.03.004_b0180","doi-asserted-by":"crossref","first-page":"1634.32","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerabilityadapted imatinib 800mg\/d versus 400mg\/d versus 400mg\/d plus interferon-a in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.jnci.2015.03.004_b0185","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jnci.2015.03.004_b0190","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s12185-014-1627-6","article-title":"Response to tyrosine kinase inhibitors in chronic myeloid leukemia: experience from a west Asian developing country","volume":"100","author":"Ali","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jnci.2015.03.004_b0195","first-page":"1","article-title":"Response to Imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: single center study","volume":"23","author":"Alsobhi","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.jnci.2015.03.004_b0200","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European Leukemia Net recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jnci.2015.03.004_b0205","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/leu.2010.215","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"25","author":"Jabbour","year":"2011","journal-title":"Leukemia"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1110036215000291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1110036215000291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T10:44:26Z","timestamp":1717843466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1110036215000291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1110036215000291"],"URL":"https:\/\/doi.org\/10.1016\/j.jnci.2015.03.004","relation":{},"ISSN":["1110-0362"],"issn-type":[{"value":"1110-0362","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience","name":"articletitle","label":"Article Title"},{"value":"Journal of the Egyptian National Cancer Institute","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnci.2015.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}